Skip to main content
Earnings Labs
Corvus Pharmaceuticals, Inc. logo

Corvus Pharmaceuticals, Inc. (CRVS)

NASDAQ·Healthcare·Biotechnology

$12.56

-6.58%

Mkt Cap $1.03B

Analyst Ratings

No recent rating data.

Price Target (13 analysts)

$35.00

Range $30.00$40.00

Implied Upside

+178.8%

Consensus $35.00 vs current $12.56